

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: PG4739	SERIAL NO: 10/066,836
	APPLICANT: BIGGADIKE, et. al.	
	FILING DATE: 02/04/2002	GROUP 1616

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
EB	A1	3,067,197	12/04/62	Agnello et al.		
	A2	3,639,434	02/01/72	Oxley et al.		
	A3	3,828,080	06/06/74	May et al.		
	A4	3,856,828	12/24/74	Phillips et al.		
	A5	3,981,694	09/21/76	Phillips et al.		
	A6	3,989,686	11/02/76	Phillips et al.		
	A7	4,093,721	06/06/78	Phillips et al.		
	A8	4,187,301	02/05/80	Edwards		
	A9	4,188,386	02/12/80	Edwards		
	A10	4,198,403	04/15/80	Alvarez		
	A11	4,261,984	04/14/81	Alvarez		
	A12	4,263,289	04/21/81	Edwards		
	A13	4,267,173	05/12/81	Draper		
	A14	4,285,837	08/25/81	Kahoda		
	A15	4,310,466	01/12/82	Edwards		
	A16	4,377,575	03/22/83	Phillips et al.		
	A17	4,607,028	08/19/86	Schmidlin		
	A18	4,710,495	12/01/87	Bodor		
	A19	4,861,765	08/29/89	Jouyveinal		
	A20	4,994,439	02/19/91	Longnecker et al.		
	A21	4,996,335	02/26/91	Bodor		
	A22	5,250,293	10/24/86	Gleich		
	A23	5,420,120	05/30/95	Boltralik		
	A24	5,707,984	01/13/98	Tjoeng et al.		
	A25	5,849,265	12/98	Li-Bovet et al.		
	A26	5,919,776	11/13/02	Hagmann et al.		
	A27	5,972,920	10/26/99	Seidel		
	A28	5,981,517	11/09/99	Bodor		
EB	A29	6,395,300	05/02	Straub, et al.		

Continued on page

FOREIGN PATENT DOCUMENTS

[illegible]


Continued on page


OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

[illegible]

Continued on page

EXAMINER	<i>Badio</i>	DATE CONSIDERED	<i>1/14/84</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4739		SERIAL NO.: 10/066,836	
				APPLICANT: BIGGADIKE, et. al.			
				FILING DATE: 02/04/2002		GROUP 1816	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continued on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
BB	B1	92/14472	09/03/92	PCT			
	B2	94/21229	09/29/94	PCT			
	B3	95/31964	11/30/95	PCT			
	B4	96/19199	06/27/96	PCT			
	B5	97/05136	02/13/97	PCT			
	B6	97/15298	05/01/97	PCT			
	B7	97/24365	07/10/97	PCT			
	B8	97/46243	12/11/97	PCT			
	B9	98/34596	08/13/98	PCT			
	B10	98/43630	10/08/98	PCT			
	B11	99/01467	01/14/99	PCT			
	B12	99/25359	05/27/99	PCT			
	B13	99/32089	07/99	PCT			
	B14	00/38811	07/06/00	PCT			
	B15	00/57401	08/16/00	PCT			
	B16	01/04118	01/18/01	PCT			
	B17	01/15744	03/08/01	PCT			
	B18	01/20331	03/22/01	PCT			
	B19	01/62722	08/30/01	PCT			
	B20	01/78736	10/25/01	PCT			
	B21	01/78739	10/25/01	PCT			
	B22	01/78741	10/25/01	PCT			
	B23	01/78745	10/25/01	PCT			
	B24	02/00199	01/03/02	PCT			
	B25	02/00679	01/03/02	PCT			
	B26	02/007767	01/31/02	PCT			
	B27	02/008243	01/31/02	PCT			
	B28	02/012285	02/14/02	PCT			
	B29	02/012265	02/14/02	PCT			
	B30	02/013868	02/21/02	PCT			
	B31	02/26723	04/04/02	PCT			
	B32	02/053186	07/11/02	PCT			
	B33	02/066422	08/29/02	PCT			
	B34	02/070490	09/12/02	PCT			
BB	B35	02/076933	10/03/02	PCT			
	Continued on page 3						
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continued on page							
EXAMINER <i>Radio</i>					DATE CONSIDERED <i>11/4/04</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4739		SERIAL NO.: 10/066,836	
				APPLICANT: BIGGADIKE, et. al.			
				FILING DATE: 02/04/2002		GROUP 1616	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
Continued on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
		B35 02/085296	10/31/02	PCT			
		B36 02/088167	11/07/02	PCT			
		B37 02/100879	12/19/02	PCT			
		B38 03/013427	02/20/03	PCT			
		B39 03/033000	04/24/03	PCT			
		B40 03/035668	05/01/03	PCT			
		B41 03/040691	05/15/03	PCT			
		B42 03/042229	05/22/03	PCT			
		B43 03/042230	05/22/03	PCT			
		B44 0004773	10/17/79	EP			
		B45 0057401	08/11/82	EP			
		B46 0135476	03/27/85	EP			
		B47 0179583	04/30/86	EP			
		B48 0416951	03/13/91	EP			
		B49 0418716	03/27/91	EP			
		B50 0521455	01/07/93	EP			
		B51 0640616	03/01/95	EP			
		B52 0646593	04/05/95	EP			
		B53 2336693	02/06/75	DE			
		B54 2538569	03/03/77	DE			
		B55 1384372	02/19/75	GB			
		B56 1438940	06/09/76	GB			
		B57 1517278	07/12/78	GB			
		B58 2079755	01/27/82	GB			
		B59 2140800	12/05/84	GB			
		B60 04208267	07/29/92	JP			
		B61 580494	10/24/86	FR			
		B62 109656	02/22/98	IL			
		B63 872389	04/02/87	ZA			
Continued on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continued on page							
EXAMINER <i>Baba</i>					DATE CONSIDERED 11/14/84		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							


RECEIVED

NOV 12 2003

TECH CENTER 1600/291

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENTATTORNEY DOCKET NO.:
PG4739SERIAL NO.:
10/066,836

APPLICANT: BIGGADIKE, et. al.

FILING DATE:
02/04/2002GROUP
1616

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

BB	C1	Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535
	C2	Richard A. Kerley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9&10), 1985, pp. 1781-1796.
	C3	R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Ldex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155
	C4	Denis J. Kertesz et al., "Thiol Esters from Steroid 17 β -Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α -Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328.
	C5	Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 - 843
	C6	John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708
	C7	John T. H. Ong et al., "Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665
	C8	Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145.
	C9	S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736
	C10	Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl- ¹⁸ F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584
	C11	Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705
	C12	Nisha Mistry et al., "Impurity profiling in bulk pharmaceutical batches using ¹⁹ F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517
	C13	N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54
BB	C14	R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209

Continued on page 5

EXAMINER

Badi

DATE CONSIDERED

11/14/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.:
 PG4739

SERIAL NO.:
 10/086,836

RECEIVED
APPLICANT: BIGGADIKI, et. al.

FILING DATE:
 02/04/2002

GROUP
 1616

NOV 12 20.
TECH CENTER 1600
U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continued on page


OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

BP	C15	Harold S. Nelson et al., "Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast," J. Allergy Clin. Immunol., Vol. 106, No. 6, December 2000, pp. 1088-1095
	C16	Gunnar Johansson et al., "Comparison of Salmeterol/Fluticasone Propionate Combination With Budesonide in Patients With Mild-to-Moderate Asthma" Clin. Drug Invest. Vol. 21, No. 9, 2001, pp. 633-642.
	C17	Bertil Pettersson et al., Re-evaluation of the classical Mycoplasma lipophilum cluster (Weisburg et al. 1989) and description of two new clusters in the hominis group based on 16S rDNA sequences," Int'l Journal of Systematic & Evolutionary Microbiology (2001) Vol. 51, pp. 633-643
	C18	Sarah A. Lewis et al., "Association of specific allergen sensitization with socioeconomic factors and allergic disease in a population of Boston women", J. Allergy Clin. Immunol., Vol. 107, No. 4, April 2001, pp. 615-622
	C19	Katherine A. Lyseng-Williamson et al., "Inhaled Salmeterol/Fluticasone Propionate Combination in Chronic Obstructive Pulmonary Disease," Am. J. Respir. Med. Vol. 1, No. 4, 2002, pp. 273-282
	C20	Jeffrey W. Millard et al., "Solubilization by cosolvents Establishing useful constants for the log-linear model," Int'l Journal of Pharmaceutics Vol. 245, 2002, pp. 153-166
	C21	C. Baumgarten et al., "Initial Treatment of Symptomatic Mild to Moderate Bronchial Asthma with the Salmeterol/Fluticasone Propionate (50/250µg) Combination Product (SAS 40023)" European Journal of Medical Research 2002, Vol. 7, pp. 1-7
	C22	Stephen J. Fowler et al., "Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclo-methasone alone" J. Allergy Clin. Immunol., Vol. 109, No. 6, June 2002, pp. 929-935
	C23	Elizabeth F. Juniper et al., "Impact of Inhaled Salmeterol/Fluticasone Propionate Combination Product versus Budesonide on the Health-Related Quality of Life of Patients with Asthma," Am. J. Respir. Med., Vol. 1, No. 6, 2002, pp. 435-440
	C24	William Busse et al., "Steroid-sparing effects of fluticasone propionate 100 µg and salmeterol 50 µg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 µg administered twice daily" J. Allergy Clin. Immunol., Vol. 111, No. 1, January 2003, pp. 57-65
	C25	UENO H ET AL, "SYNTHESIS AND EVALUATION OF ANTIINFLAMMATORY ACTIVITIES OF A SERIES OF CORTICOSTEROID 17. ALPHA -ESTERS CONTAINING A FUNCTIONAL GROUP" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, Vol. 34, No. 8, August 1991, pp. 2468-2473
	C26	PETER J BARNES, "Novel approaches and targets for treatment of Chronic Obstructive Pulmonary Disease" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 160, 1999, pp. S72-S79
	C27	B. J. O'CONNOR, "Combination Therapy", PULMONARY PHARMACOLOGY AND THERAPEUTICS, Vol. 11, No. 5/6, 1998, pp. 397 - 399
BB	C28	PETER J BARNES, "Chronic Obstructive Pulmonary Disease: new opportunities for drug development" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, Vol. 19, No. 10, 1998, pp. 415 - 423

Continued on page 6

EXAMINER
DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 606; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DCKET NO.: PG4739	
		SERIAL NO.: 10/068,836	
		APPLICANT: BIGGADIKE, et. al. FILING DATE: 02/04/2002	
		GROUP 1616	

U.S. PATENT DOCUMENTS						
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS						
Document Number	Publication Date	Country	Class	Subclass	Translation Yes No	

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	
BB C29 C30 C31 C32 C33 C34 C35 C36 C37 C38 C39 C40 C41 C42	SIMON BOWLER, "Long acting beta agonists", AUSTRALIAN FAMILY PHYSICIAN, Vol 27, No. 12, 1998, pp. 1114-1118 NAEDLE-RISHA R ET AL, "Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long acting beta-agonists with inhaled corticosteroids", THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, Vol 101, No. 9, September 2001, pp.2001-09 T VAN DER MOLEN ET AL, "EFFECTS OF THE LONG ACTING BETA AGONIST FORMOTEROL ON ASTHMA CONTROL IN ASTHMATIC PATIENTS USING INHALED CORTICOSTEROIDS", Vol. 52, No. 6, 1997, pp. 535-539 B.N. LUTSKY et al, "A Novel Class of potent Topical Anti-inflammatory Agents: 17 Benzoylated, 7 - Halogeno Substituted Corticosteroids", Arzneimittel Forschung, Vol. 29, No. 11, Nov. 1979, pp. 1662-1667 PETER J. BARNES, "Efficacy of Inhaled Corticosteroids in Asthma", The Journal of Allergy and Clinical Immunology, Vol. 102, No. 4, pp. 531-538 US Publication No. 2002/0081266 publ. on 06/27/02 US Publication No. 2002/0103392 publ. on 08/01/02 US Publication No. 2002/0165211 publ. on 11/07/02 US Publication No. 2002/0173496 publ. on 11/21/02 US Publication No. 2002/0177581 publ. on 11/28/02 US Publication No. 2003/0073676 publ. on 04/17/03 US Publication No. 2003/0109511 publ. on 06/12/03 US Publication No. 2003/0144257 publ. on 07/31/03 US Publication No. 2003/0158163 publ. on 08/21/03

RECEIVED
 NOV 12 2003
 TECH CENTER 1600/2900

Continued on page

EXAMINER Badio	DATE CONSIDERED 1/14/04
---	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 409; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.